Purpose Recent studies suggest that adult pituitary stem cells may play a role in pituitary tumorigenesis. We sought to explore whether the Glial cell-line derived neurotrophic factor receptor alpha 2 (GFRa2), a recently described pituitary stem/progenitor marker, might be differentially expressed in pituitary adenomas versus normal pituitary. Methods The expression of GFRa2 and other members of the GFR receptor family (GFRa1, a3, a4) were analyzed using RT-PCR, western blot, and immunohistochemistry in 39 pituitary adenomas, 14 normal pituitary glands obtained at autopsy, and cDNA from 3 normal pituitaries obtained commercially. Results GFRa2 mRNA was *2.6 fold under-expressed in functioning adenomas (p \ 0.01) and *3.5 fold over-expressed in non-functioning adenomas (NFAs) (p \ 0.05) compared to normal pituitary. Among NFAs, GFRa2 was significantly over-expressed (*5-fold) in the gonadotropinoma subtype only (p \ 0.05). GFRa2 protein expression appeared to be higher in most NFAs, although there was heterogeneity in protein expression in this group. GFRa2 protein expression appeared consistently lower in functioning adenomas by IHC and western blot. In normal pituitary, GFRa2 was localized in Rathke's remnant, the putative pituitary stem cell niche, and in corticotropes. Conclusion Our results suggest that the pituitary stem cell marker GFRa2 is under-expressed in functioning adenomas and over-expressed in NFAs, specifically gonadotropinomas. Further studies are required to elucidate whether over-expression of GFRa2 in gonadotropinomas might play a role in pituitary tumorigenesis.
Introduction
In recent years, several lines of evidence have converged to establish the presence of a stem/progenitor niche within the adult pituitary gland [1] . This stem cell niche is localized in the marginal zone (MZ), the cell layer containing remnants of Rathke's pouch, and is characterized by the expression of various embryonic and pituitary-specific transcription factors, cell adhesion proteins, and neuronal-related markers [2] . Cells expressing these stem cell markers have been isolated and induced to differentiate into each lineage of the anterior pituitary [2] . Since normal developmental pathways are often deregulated in neoplasms, there has been recent interest in the relationship between adult pituitary stem cells and tumorigenesis [3] . In mouse models, over-expression of the WNT/b-catenin pathway leads to the development of tumors resembling the human adamantinomatous craniopharyngioma [4] , while conditional deletion of the retinoblastoma tumor suppressor results in silent corticotrope adenomas from progenitor cells expressing the embryonic transcription factor Pax7 [5] . There is one study that suggests the presence of stemlike cells in two human pituitary adenomas [6] .
Based on the above-mentioned premises, we sought to study expression of a recently described pituitary stem/ progenitor cell marker, Glial cell-line derived neurotrophic factor receptor alpha 2 (GFRa2), in human pituitary adenomas and normal human pituitary [7] . This receptor belongs to a family of four RET co-receptors (GFRa1-a4) involved in central and peripheral nervous system development [8] . In rodents and humans, cells co-expressing GFRa2 and the pituitary-specific transcription factor Prophet of Pit-1 (PROP-1) are localized at the MZ, and in rodents they were shown to display pluripotency and selfrenewal capacity [7] . GFRa1 and RET have previously been studied in pituitary adenomas and were found to be expressed predominantly in GH-secreting adenomas, while GFRa3 was recently shown to be expressed in a minority of adamantinomatous craniopharyngiomas [9, 10] . To the best of our knowledge, the expression of GFRa2 has not been systematically studied in pituitary adenomas. We hypothesized that GFRa2 might be over-expressed in some clinically non-functioning pituitary adenomas (NFAs) because at least a minority of these tumors are hormonally silent and lack cell-type specific differentiation [11] . We used intraoperative-obtained human pituitary tumor tissue from clinically non-functioning and hormone-secreting pituitary adenomas, as well as normal pituitary tissue obtained from autopsy and a commercial source.
Methods

Tumors samples and controls
All samples were obtained under Johns Hopkins University IRB approval, with written informed consent obtained prior to surgery. During the period of study (2010) (2011) (2012) , 43 pituitary adenomas were obtained at the time of surgery and were flash frozen for RNA and protein. After extraction, sufficient RNA quantity was available for 39 adenomas. All samples represented independent tumors (i.e. no repeat surgeries) from different individuals not suspected of having a familial pituitary adenoma syndrome. Limitations of sample size meant that some tumors had sufficient material for RNA analysis but not for protein analysis.
A total of 17 normal pituitary glands were used as controls. Fourteen pituitary glands were obtained at autopsy from individuals with no history or gross evidence of pituitary disease. Additionally, cDNA from 3 normal pituitaries was purchased commercially from BioChain, Inc. (Newark, CA) as external controls. These external controls were used to verify the quality of RNA obtained from our autopsy samples, since the post-mortem interval was generally much shorter in the commercially obtained samples (mean ± SD: 5 ± 1 h) compared to the internally obtained samples (mean ± SD: 27 ± 11 h). Details related to autopsy specimens and their use in the study are provided in Supplemental Table 1 . For RT-PCR experiments, the mean age at death for autopsy subjects (mean ± SD: 63 ± 3 years) was higher than the mean age at surgery for the study subjects (mean ± SD: 48 ± 15 years) (p \ 0.01). There was an even gender distribution in both study subjects and controls.
Tumor classification
Clinico-pathologic classification of pituitary adenomas was based on a combination of clinical and biochemical data, histology, immunostaining of pituitary hormones, and, in some cases, RT-PCR of lineage-specific transcription factors (Table 1) [12] [13] [14] [15] . Histopathologic review was independently conducted by a neuropathologist (P.B.) who was blinded to the clinical diagnosis, and the clinical diagnosis was made by the treating endocrinologist. In cases of clinically NFA where hormone staining was completely absent or the staining pattern did not align clearly with an adenoma subtype (n = 9), RT-PCR of tumor tissue for lineage-specific transcription factors was used to confirm the cytological differentiation of the tumor [16] [17] [18] . The following genes were used to determine cytological differentiation: steroidogenic factor 1 (SF1), GATA-2, LHb, FSHb, alpha-glycoprotein subunit (aGSU), and estrogen receptor 1 (ESR1) indicated gonadotrope origin; TBX19 and POMC indicated corticotrope origin; thyrotroph embryonic factor (TEF) and TSHb indicated thyrotrope origin; prolactin (PRL) indicated lactotrope origin; growth hormone (GH) indicated somatotrope origin. In cases of NFAs where combined IHC and RT-PCR data did not indicate a clear cytological differentiation, tumors were deemed ''silent unclassified.'' Although some tumors displayed hormone staining and transcription factor patterns potentially indicative of a plurihormonal cell type (i.e. silent subtype 3 adenoma), we could not exclude the possibility that this was the result of trapped non-tumoral cells. We considered tumors with hormone staining and transcription factor expression across multiple pituitary lineages to be ''unclassified.'' RT-qPCR RNA was extracted from all samples using Qiagen's RNeasy Mini kit (Valencia, CA) following manufacturer's recommendations, and genomic DNA contamination was eliminated using Invitrogen's DNA free system (Grand Island, NY). One lg of total RNA was reverse transcribed using Invitrogen's SuperScript III first strand synthesis system. All primers were used at final concentration of 5 lmol. All RT-qPCR reactions were heat denatured for 10 min at 95°C, followed by 30 cycles of 95°C for 15 s, 60°C for 30 s, 70°C for 30 s, and a final extension step at 72°C for 10 min. Water and cDNA in the absence of reverse transcriptase were used as negative controls. The primers used are shown in Supplemental Table 2 . For quantitative RT-PCR, we used Applied Biosystems SYBR Green PCR master mix (Carlsbad, CA) at a final volume of 15 ll for all reactions. 0.2 ll of diluted cDNA was used per reaction, performed in triplicate, and analyzed using Applied Biosystems 7300 Real-TIME PCR system. The double delta Ct method was used to determine the level of expression as normalized to reference gene GAP-DH and is expressed as fold change relative to a purchased external pituitary control (Autopsy Sample 1). This sample was chosen as the comparator because of the short postmortem interval (and consequently lower potential risk of RNA degradation) and close approximation in age of the deceased and mean age of study subjects. For qualitative RT-PCR, platinum PCR Supermix from Invitrogen was used at a final volume of 20 ll.
Immunohistochemical detection
Hormone immunostains used for diagnostic purposes were performed by the Immunopathology Laboratory in the Department of Pathology using enzymatic DAB reaction. IHC staining of GFRa2 alone or in combination with other antigens was performed using immunofluorescence (38 tumor samples studied). The following panel of antibodies was used at 1:100 dilution: mouse anti-ACTH (Santa Cruz, SC-69648), rabbit anti-ACTH (Abcam, AB74976), goat anti-GH (Santa Cruz, SC-10365), mouse anti-GH (Santa Cruz, SC-51602), goat anti-PRL (Santa Cruz, SC-7805), rabbit anti-PRL (Spring Bioscience, E17490), goat antiTSHb (Santa Cruz, SC-7815), rabbit anti-TSHb (Abcam, AB64378), goat anti-FSHb (Santa Cruz, SC-7797), rabbit anti-FSHb (Abcam, AB8746), mouse anti-LHb (Abcam, AB15226), rabbit anti-LHb (Abcam AB76902), mouse anti-S100b (Millipore, MAB079-1), rabbit anti-a-GSU (Abcam, AB92738), mouse anti-a-GSU (Novus Biologicals, NB-100-62265), mouse anti-GFAP (Millipore, MAB3402). The following antibodies were used at 1:50 dilution: goat anti-neurturin (Abcam, AB63949), goat antiRet (Santa Cruz, SC-1290), rabbit anti-Ret (Santa Cruz, SC-167), mouse anti-Ret (Abcam, AB1840). Rabbit antiGFRa2 (QED Bioscience, QED1135) was used at 1:50 dilution for IHC. Each commercial antibody was verified to have reactivity against the human protein of interest. Omission of primary antibody was used in all experiments as a negative control and no staining was observed. The following panel of secondary antibodies was used at 1:500 dilution: Donkey anti-rabbit 594 (Invitrogen, A21207), Donkey anti-goat 488 (Invitrogen, A11055), and Donkey anti-mouse 488 (Invitrogen, A21202).
Formalin-fixed paraffin embedded tissues were deparaffinized and rehydrated then immersed in 0.1 % Sudan Black B (Sigma, St. Louis, MO) in 70 % Ethanol for 20 min to minimize autofluorescence [19] . Antigen retrieval was performed using sodium citrate buffer (10 mM, 0.05 % Tween-20, pH 6.0) at 95°C for 20 min. PBS was used to wash stains and dilute antibodies when GFRa2 was stained alone. For every primary antibody and pituitary sample, the tissue was stained with and without primary antibody and omission of the primary antibody resulted in no labeling. In addition, when tissue slices obtained from the same pituitary were treated with serially diluted primary antibody concentrations and identical fixation conditions, staining went from dense to light to imperceptible. For co-immunostaining of cell surface and cytoplasmic antigens, a mild detergent (0.02 % Tween-20 in PBS) was used in the antibody diluent to permit penetration of antibodies and detection of cytoplasmic antigens without compromising the staining of cell surface antigens. Primary antibodies were incubated overnight followed by secondary antibodies for 1 h in the dark at room temperature and 15 min of DAPI nuclear counterstaining. A blocking step with either donkey or goat serum was used between the two antigen detection cascades. Images of GFRa2 immunostaining were acquired at the same exposure time.
Western blot analysis
Twenty lg of protein were loaded onto a 4-12 % SDSpolyacrylamide gel. Proteins were transferred onto a PVDF membrane and probed with monoclonal mouse anti-human GFRa2 antibody (R&D Systems, Minneapolis, MN) at 1:500 dilution. Twenty-one tumor samples had sufficient protein concentration to permit loading of 20 lg per well for analysis by Western blot.
Statistical analysis
GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. Two-tailed t test (Mann-Whitney test) was used for comparison of means, two-sided Chi square test with Fisher's exact test was used for comparison of proportions, and one-way Analysis of Variance (ANOVA) was used in multiple group comparisons with Bonferroni's post hoc test.
Results
Gene expression profile of GFRa2 in pituitary adenomas
GFRa2 was significantly under-expressed in functioning pituitary adenomas and over-expressed in NFAs relative to normal pituitary (Fig. 1) . In addition, NFAs showed significantly higher expression of GFRa2 relative to all functioning adenomas combined, the majority of which were GH-secreting adenomas. The normal pituitary samples had similar expression of GFRa2 compared to the reference sample. Since GFRa2 gene expression was significantly higher in the NFAs, we explored whether there were differences in its expression among the subtypes of NFAs. We found that GFRa2 was significantly overexpressed (4 
Localization of GFRa2 immunostaining in normal pituitary
In the normal pituitary, GFRa2 immunostaining was observed most intensely in the MZ at the interface of the posterior and anterior pituitary (Fig. 2a) . The majority of cells within Rathke's remnant cysts stained positively for GFRa2. Co-immunostaining of GFRa2 with each of the anterior pituitary hormones showed GFRa2 immunoreactivity most strongly in corticotropes. GFRa2 staining was seen in clusters surrounding gonadotropes but there was not clear staining of GFRa2 seen within this cell type (Fig. 2b) .
Weak co-immunostaining of GFRa2 with its co-receptor RET and stronger co-immunostaining with its ligand neurturin was observed in the normal pituitary (Fig. 3a) . We also investigated whether GFRa2 might be expressed in folliculostellate (FS) cells of the anterior pituitary. These hormonally null cells, which form a functional neural network within the gland, have been proposed to have progenitor properties [20] . We did not find significant GFRa2 expression in FS cells, with only rare co-staining of GFRa2 and the FS cell markers S100b or GFAP being observed (Fig. 3b) .
Immunohistochemical staining of GFRa2 in pituitary adenomas
Immunohistochemical staining of GFRa2 among pituitary tumors revealed that gonadotropinomas showed the most intense and diffuse staining, with scattered cells positive for both GFRa2 and gonadotrope hormones (Fig. 4a-d) .
Within an individual gonadotropinoma, there was heterogeneity in the pattern of GFRa2 staining. In some areas, the number of GFRa2 positive cells exceeded the number of hormone-positive cells (Fig. 4a-b) , while in other areas, the opposite pattern was observed (Fig. 4c, d ). In two ACTH-secreting adenomas, one tumor showed focal areas of GFRa2/ACTH co-localization (Fig. 4e) , while the other tumor showed both focal and diffuse GFRa2 staining (Fig. 4f-h ). GFRa2 immunostaining was absent in tumors of the Pit-1 lineage (PRL, GH, and TSH-secreting adenomas) (Fig. 4i-l) .
Correlation of GFRa2 protein and mRNA expression
Consistent with the mRNA results, western blot suggested lower GFRa2 expression in functioning adenomas relative to normal pituitary (Fig. 5) . Although several NFAs appeared to have higher protein expression of GFRa2 by western blot, GFRa2 mRNA and protein expression did not directly correlate for all tumors. Among tumors that were analyzed by both RT-PCR and Western Blot, a concordant pattern of expression was observed in 11 of 20 (55 %). Among the 9 discordant cases, 7/9 (78 %) showed overexpression by RT-PCR and appeared to be under-expressed relative to control by Western Blot, while 2/9 (22 %) showed under-expression by RT-PCR and higher protein Fig. 1 Real time PCR analysis of GFRa2 gene expression in normal pituitary (CON, n = 13), all pituitary tumors (TUM, n = 39), nonfunctioning adenomas (NFA, n = 21), functioning adenomas (FUNC, n = 18), GH-secreting adenomas (GH, n = 14), ACTH-secreting adenomas (ACTH, n = 2), prolactin-secreting adenoma (PRL, n = 1), and TSH-secreting adenoma (TSH, n = 1). Data are presented as mean transcript fold changes relative to one normal control sample and normalized to GAPDH, with each bar representing the standard error of the mean (SEM). *p \ 0.05, **p \ 0.01 (relative to control when indicated above error bars or between groups as specified by brackets). GFRa2 is over-expressed in NFAs (relative to normal pituitary, functioning adenomas, and GH adenomas) expression. Among the functioning adenomas, 6/7 (86 %) had concordant mRNA and protein patterns, while only 5/12 (41 %) of the NFAs showed concordance.
Discussion
Cancer stem cells have long been reported in many primary brain malignancies [21] [22] [23] , but whether stem cells exist in benign tumors, such as pituitary adenomas, remains uncertain [3] . Historically, cancer stem cells have been isolated experimentally from solid tumors (i.e. with flow-activated cell cytometry) using markers specific for normal stem cells of the same organ [24] . In the normal adult pituitary gland, candidate stem cells have been shown to express the embryonic stem cell markers Sox2 and Sox9, the neuronal marker Nestin, and co-expression of GFRa2/Prop1 [2] . While this study was not designed to demonstrate the existence of stem cells in pituitary adenomas, the comprehensive gene expression profile of a stem cell marker in pituitary adenomas provides preliminary evidence that progenitor/ stem cells could be involved in adenoma cytogenesis. In this study, we demonstrate that GFRa2 is underexpressed at the gene and protein level in functioning pituitary tumors, particularly those of the Pit-1 lineage (GH, PRL, and TSH). This finding indirectly supports the candidacy of GFRa2 as a pituitary stem-related marker, since most of the functioning pituitary tumors we studied are derived from cells of the Pit-1 lineage, the most terminally differentiated cells in pituitary development. By IHC, we did not observe any staining of GFRa2 in tumors of the Pit-1 lineage (GH, PRL, TSHb) and there was negligible protein expression by western blot in these tumor types.
LH/GFRα
Contrary to the other functioning pituitary adenoma types, GFRa2 mRNA was not under-expressed in ACTHsecreting adenomas, and there was diffuse and focal immunostaining of GFRa2 seen in these tumors. The unique gene and protein expression pattern of ACTHsecreting tumors among the functioning adenomas is not unexpected, as ACTH-secreting cells arise from an earlier precursor cell during pituitary differentiation [25] . Furthermore, the pattern of GFRa2 expression in ACTH tumors was in line with our observations in normal pituitary tissue, where GFRa2 stained most intensely with corticotropes. In this respect, our findings differ from those of Garcia-Lavandeira et al. [7] who first established GFRa2 as a stem cell marker within the pituitary gland. In their study, GFRa2 was restricted mainly to Rathke's remnant, with some scattered staining observed within the AP. While we observed a similar pattern of staining in the MZ (the pituitary stem cell niche), we also observed GFRa2 staining in corticotropes and adjacent to (but not within) gonadotrope cell clusters in the AP bordering the MZ. The reasons for this difference are not readily apparent, but it deserves mention that the observation of GFRa2 expression within a differentiated pituitary cell type casts some doubt on the candidacy of this receptor as an independent pluripotent stem cell marker. While we did not explore this directly, it is plausible that GFRa2-positive/PROP-1-positive cells (as shown by Garcia-Lavandeira et al.) are restricted to the MZ and maintain pluripotency, while GFRa2-positive/PROP-1 negative cells at the border of the MZ represent more committed progenitor cells. Contrary to the functioning adenomas, GFRa2 mRNA was over-expressed in NFAs. This heterogeneous group of pituitary tumors has no clinical evidence of hormone hypersecretion, and therefore adenomas belonging to this group can also be described as silent [16] . NFAs are comprised predominantly of gonadotropinomas, although adenomas derived from any pituitary lineage can be hormonally silent. We had initially hypothesized that GFRa2 would be over-expressed in the NFAs because at least a minority of these tumors are hormonally null and lack celltype specific differentiation. In fact, after careful cytologic characterization of the silent adenomas by PCR, we were unable to identify any cases of true null cell adenomas; consistent with current understanding, most of the NFAs were found to belong to the gonadotropin lineage [16] . Since we included all types of adenomas and classified the silent adenomas according to their cytological differentiation, we were able to show that GFRa2 mRNA is specifically over-expressed in gonadotropinomas. It does not appear that GFRa2 is playing a role in the ''silencing'' of adenomas per se, since we only observed higher expression in the gonadotropinomas, but not other types of silent adenomas. Rather, this finding suggests that GFRa2 may play a role in modulation or differentiation of gonadotrope cells.
Although we observed statistically significant overexpression of GFRa2 in NFAs by RT-PCR, this did not always correlate with the protein expression observed by IHC and western blot. Generally, western blot and IHC suggested higher protein expression in NFAs compared to the other adenoma types, however some NFAs with high mRNA expression did not appear to have significant protein expression by either method of detection. Similarly, some NFAs that appeared to have high protein expression had very low gene expression. Discordant gene and protein expression is not uncommon in malignancies [26] [27] [28] . It has been shown that different cell types within a tumor can display variable concordance in expression at the gene and protein level [28, 29] It is possible that different pituitary tumor cell types may have variable degradation rates of mRNA and protein or differences in post-translational modifications. The higher concordance between mRNA and protein in the functioning adenomas compared to the NFAs may be a reflection of greater homogeneity with respect to cytologic differentiation among functioning adenomas compared to non-functioning adenomas (NFAs). While gonadotropinomas showed variable expression of LHb, FSHb, and aGSU (potentially reflecting differing stages of differentiation), most of the functioning adenomas showed pure expression of a single hormone. Ultimately, since it is the protein concentration that determines cellular function, the overexpression of GFRa2 mRNA in NFAs can be interpreted only as correlative rather than causative, and further studies would be needed to determine whether GFRa2 exerts any effect on gonadotrope cell growth or differentiation. By inference from our findings in both normal and tumor tissue, it appears that GFRa2 is present in corticotrope and gonadotrope cell types. Since corticotrope and gonadotrope differentiation arise from a common Rathke's pouch progenitor, it is conceivable that GFRa2 is a marker of a progenitor cell common to these lineages [25, [30] [31] [32] [33] [34] [35] . Interestingly, the finding of GFRa2 immunostaining most strongly in ACTH cells in the normal pituitary and in cells adjacent to a-GSU cell clusters follows the expected differentiation pattern in which ACTH and a-GSU appear contemporaneously [30, 36] . In the adult pituitary gland, LH-producing gonadotrope cells form a network alongside the pre-established corticotrope network and the two lineages maintain direct contact throughout adulthood [37] . Furthermore, it has recently been demonstrated that some silent corticotropinomas share characteristics of gonadotropinomas, including cytological differentiation markers and ultrastructural features [38] . Given these observations, an alternative role for GFRa2 might be to facilitate ''crosstalk'' between gonadotrope and corticotrope cells.
GFRa2 signaling occurs via homodimerization of the co-receptor RET and initiation of downstream intracellular pathways [8] . Although its co-receptor RET and ligand neurturin showed co-immunoreactivity with GFRa2 in the normal pituitary, we did not find parallel gene expression patterns in pituitary adenomas. Consistent with a previous study, RET was under-expressed in NFAs [9] . Expression of the GFRa2 ligand neurturin was slightly higher in NFAs relative to controls, but this difference was marginal and the expression was still lower than that of the reference control sample. While further in vitro studies would be required to elucidate the intracellular signaling pathways involved in pituitary tumors, these findings suggest the possibility of a RET-independent GFRa signaling mechanism, which has been described [8] .
Given the role of FS cells in pituitary paracrine modulation and their putative stem cell role, we explored whether GFRa2 might be expressed in FS cells of the normal pituitary. We found that only rare numbers of GFRa2 positive cells expressed FS cell markers, particularly S100b. FS cells are not usually found in abundance in pituitary adenomas, making it unlikely that trophic stimulation of gonadotropes via GFRa2 signaling is a significant driver of tumor growth [17] . However, it is worth mentioning that Garcia-Lavandeira et al. [7] noted that half of the GFRa2/Prop1 stem cells in the rodent pituitary expressed S100b, suggesting that these stem cells could give rise to both hormone-producing and neuron-like cells. Those authors posit that these stem cells could thereby play a role in controlling the physiological demands on the pituitary gland (i.e. puberty, lactation, growth, etc.) throughout the lifetime of the organism [7] .
A main strength of our study is the representation of each adenoma type, with a relatively large sample size of NFAs and GH adenomas. Inclusion of the rare thyrotropinoma allowed us to infer that GFRa2 is not implicated in tumors of the Pit-1 lineage. In addition, we had a large sample of control pituitary glands, with validation of our internal autopsy samples using commercially obtained controls. We comprehensively classified the NFAs using RT-PCR of transcription factors in some cases to determine the cytological differentiation. A limitation of our study is the small sample number of ACTH and TSH tumors, but this reflects the rarity of these tumors and the generally small size of these tumors, which can make it difficult to obtain workable amount of material in some cases. In addition, although we were able to study protein expression by IHC for all tumors, we did not have sufficient samples to analyze protein expression by Western blot for all tumors.
